Alterations of the retinoblastoma and p16 pathway correlate with promoter methylation in malignant fibrous histiocytomas

Ulrich Brinck, Thilo Schlott, Steffi Störber, Jerzy Stachura, Pawel Bortkiewicz, Wolf Dieter Nagel, Frank Michael Hasse, Carlos Cordon-Cardo, Gösta Fischer, Monika Korabiowska

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Recent reports indicate that the alterations in the p16 and pRb pathways can influence tumour progression and poor prognosis in several tumours. The objective of this study was to analyse p16 and pRb expression in161 patients with malignant fibrous histiocytomas (MFH). By immunohistochemistry, p16 and pRb were demonstrated in 25% and 56% of MFH, respectively. Cox regression analysis demonstrated an independent prognostic influence of both genes. Generally, the loss of p16 and pRb expression correlated with poorer prognosis. Promoter methylation of p16 was found in 16/42 of p16 negative MFH and of pRb in 2/42 of pRb-negative MFH. It can be concluded that p16 and pRb alterations play an important role in the progression of soft tissue sarcomas.

Original languageEnglish
Pages (from-to)3461-3465
Number of pages5
JournalAnticancer Research
Volume26
Issue number5 A
StatePublished - Sep 2006
Externally publishedYes

Keywords

  • Fibrous histiocytoma
  • Promoter methylation
  • p16
  • pRb pathway

Fingerprint

Dive into the research topics of 'Alterations of the retinoblastoma and p16 pathway correlate with promoter methylation in malignant fibrous histiocytomas'. Together they form a unique fingerprint.

Cite this